SCHEMBL384065

SCHEMBL384065

CCCCCC(=O)OC[C@@](CC)(CO)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.41
HRH3 Q9Y5N1 1/20 0.38
PAM P19021 2/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
DUSP3 P51452 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.36
TSHR P16473 1/20 0.36
PRKCA P17252 3/20 0.36
PRKCE Q02156 1/20 0.36
PRKCQ Q04759 1/20 0.36
PRKCD Q05655 1/20 0.36
DNM1 Q05193 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CTSK P43235 1/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455191 1.00 DGKA (0.41) DGKAHRH3PAMLMNAKDM4E
SCHEMBL387155 0.84 DGKA (0.42) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL1454885 0.84 DGKA (0.42) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL27039140 0.82 DGKA (0.48) DGKAHRH3PRKCAPRKCEPRKCQ
SCHEMBL30768263 0.81 DGKA (0.49) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL386260 0.79 DGKA (0.41) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL78913 0.78 TDP1 (0.42) KDM4EMEN1KMT2AALDH1A1CTSK
SCHEMBL384057 0.77 DGKA (0.41) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL5166025 0.77 DGKA (0.41) DGKAPAMLMNAKDM4EDUSP3
SCHEMBL17135366 0.76 HRH3 (0.60) DGKAHRH3PAMLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-20070191468-A1 Amino alcohol compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-08-16 US disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
EP-1733724-A1 AMINO ALCOHOL COMPOUND Sankyo Company, Limited (JP) 2006-12-20 EP disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT DGKA 2180/4885HRH3 33/4885PAM 752/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 DGKA 3411/4885HRH3 2/4885PAM 553/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB DGKA 3512/4885HRH3 4/4885PAM 1235/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 DGKA 1896/4885HRH3 1/4885PAM 1017/4885
US-20070191468-A1 Amino alcohol compound ADH1A, ADH1C, BCAT1 DGKA 2797/4885HRH3 977/4885PAM 1784/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A DGKA 1312/4885HRH3 30/4885PAM 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.